TrxR inhibitor D9 

TrxR inhibitor D9 is a potent and selective inhibitor of thioredoxin reductase (TrxR), with an EC₅₀ of 2.8 nM. TrxR inhibitor D9 has the capability to inhibit tumor proliferation both in vitro and in vivo^[1][2].

EC50: 2.8 nM (TrxR)^[1]

TrxR inhibitor D9 (0.1-1 μM; 72 h) inhibits the cell proliferation with IC₅₀s of 0.03 and 0.1 μM for MCF-7 and HT-29 cells, respectively^[1].
TrxR inhibitor D9 (72 h) completely inhibits all cancer cells (A549, KB, MDA MB-231, HeLa, MCF-7 and HT-29) viability at the concentration of 0.60 μM, and the IC₅₀s of all cancer cells could be as low as 0.55 μM, and dose not significantly affects normal cells viability^[1].
TrxR inhibitor D9 (0.8 μM; 4 and 8 h) induces HT-29 cells necrosis/apoptosis^[1].
TrxR inhibitor D9 (2-20 nM; 1-60 s) inhibits TrxR activity in a concentration-dependent manner^[1].
TrxR inhibitor D9 (1-1000 nM) does not significantly inhibits the catalytic activity of glutathione reductase (GR) even when the concentration increases to more than 1000 nM^[1].
TrxR inhibitor D9 (0.4 μM) could effectively avoid the ligand exchange with albumin^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

TrxR inhibitor D9 (5 mg/kg; i.v. once every 2 d for 15 d) effectively inhibits the growth of tumors in mice^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

596.43

C₂₅H₂₀AuOPS

1527513-89-8

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zhang D, et, al. Synthesis and molecular recognition studies on small-molecule inhibitors for thioredoxin reductase. J Med Chem. 2014 Oct 9;57(19):8132-9.  [Content Brief]

  [2]. Lin YX, et, al. pH-Sensitive Polymeric Nanoparticles with Gold(I) Compound Payloads Synergistically Induce Cancer Cell Death through Modulation of Autophagy. Mol Pharm. 2015 Aug 3;12(8):2869-78.  [Content Brief]